Transgene previously presented in a rapid oral presentation at the ASCO conference in June 2025, that all patients from Phase I who received TG4050 remained disease-free after a minimum of 2-year ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback